

Baldwin Park, CA, February 2020 –

Sensigent is supporting COVID-19 efficacy testing for screening and early detection.

Multiple groups worldwide are developing clinical tests using Sensigent products and technologies for screening and early detection of major diseases, including heart disease, COPD, asthma, diabetes, cancer and bacterial infections of the lung, GI and urinary tracts. These tests measure breath, urine and other ex-vivo samples quickly and non-invasively.

Recently, several investigations have been started or are proposed to develop a breath screening test for coronavirus infection (COVID-19). Sensigent is pleased to support this effort through provision of instrumentation, sensors, software and testing supplies. Contact Sensigent at sales@sensigent.com for more information on the Cyranose® 320 and our other products for clinical testing.